Renaissance Capital logo

Silk Road Medical Priced, Nasdaq: SILK

Sells medical devices to treat carotid artery disease.

Industry: Health Care

First Day Return: +80.9%

Industry: Health Care

We are a medical device company focused on reducing the risk of stroke and its devastating impact. We believe a key to stroke prevention is minimally-invasive and technologically advanced intervention to safely and effectively treat carotid artery disease, one of the leading causes of stroke. We have pioneered a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which we seek to establish as the standard of care. TCAR relies on two novel concepts, minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain, and combines the benefits of innovative endovascular techniques with fundamental surgical principles. TCAR using our portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality profile of current treatment alternatives while providing a reduction in long-term stroke risk. We are the first and only company to obtain FDA approvals, secure specific Medicare reimbursement coverage, and commercialize products engineered and indicated for use in TCAR. As of December 31, 2018, more than 7,750 TCAR procedures have been performed globally, including more than 4,600 in 2018.
more less

Silk Road Medical (SILK) Performance